Glycomine

Glycomine is a San Carlos, CA biotechnology company developing orphan drugs for the treatment of congenital disorders of glycosylation which are rare inborn errors of metabolism in which glycosylation (sugar coating) of a variety of tissue proteins and/or lipids is deficient or defective. The company’s lead program is targeting PMM2-CDG (or CDG-1a) a genetic metabolic disorder caused by a deficiency of cytosolic enzyme phosphomannomutase 2. Remiges participated in the Company’s Series B extension financing.